FierceBiotech: Werewolf Therapeutics uncloaks with $56M and shape-shifting cancer meds

November 20, 2019

It’s a full moon for Werewolf Therapeutics as the company comes out of stealth with $56 million and an approach it believes can cut through the toxic effects that have limited the use of certain cancer-killing agents.

Read the full story

FierceBiotech

By Amirah Al Idrus

March 3, 2020

Designing conditionally activated immune stimulators that attack cancer cells

As seen in Nature Biopharma Dealmakers Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered Read More

December 17, 2019

Pittsburgh Business Times: UPMC Enterprises invests in immunotherapy startup

UPMC Enterprises is part of the investor group for a Massachusetts startup that focuses on immunotherapies, the types of treatments that Read More

December 13, 2019

Smart Business Dealmakers Pittsburgh: UPMC Enterprises Invests In Werewolf Therapeutics

UPMC Enterprises joined a Series A funding round of $56 million for Werewolf Therapeutics. The Cambridge, Massachusetts-based oncology biotherapeutics company is developing Read More

Share this article: